Early experience using calcineurin-free protocol in recipients of high-risk cadaver renal transplants.
El-Sabrout
R
R
Departments of Transplantation/Vascular Surgery, New York Medical College, Valhalla, New York, USA.
Delaney
V
V
Butt
F
F
Qadir
M
M
Rashid
I
I
Hanson
P
P
Butt
K
K
D002102:Cadaver; D019703:Calcineurin; D005500:Follow-Up Studies; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D009518:New York; D044469:Racial Groups; D018570:Risk Assessment; D020123:Sirolimus / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D007166:Immunosuppressive Agents; D019703:Calcineurin; D009173:Mycophenolic Acid; D020123:Sirolimus